title: Intraperitoneal insulin therapy for a patient with type 1 diabetes with insulin injection site inflammation.
abstract: A 36-year-old man with type 1 diabetes developed skin inflammation at the site of subcutaneous insulin injection after 10 years of basal bolus subcutaneous insulin therapy. This inflammation led to poor insulin absorption, poorly controlled blood glucose and subsequently to ketoacidosis. The problem persisted despite a trial of continuous subcutaneous insulin infusion. The patient went on to be treated with continuous intraperitoneal insulin infusion. Three months after the procedure, he was achieving good glucose control and was able to resume his normal life, with the only complication being an episode of cellulitis surrounding the port site.
authors.affiliation: The Queen Elizabeth Hospital, Birmingham, UK.
authors.forename: Siang Ing
authors.initials: SI
authors.lastname: Lee
authors.affiliation: Clinical and Experimental Medicine, The Medical School, University of Birmingham, UK Department of Diabetes, The Queen Elizabeth Hospital, Birmingham, UK.
authors.forename: Parth
authors.initials: P
authors.lastname: Narendran
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002481:Cellulitis / Q000209:etiology; D003872:Dermatitis / Q000209:etiology*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000209:etiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D007263:Infusions, Parenteral / Q000009:adverse effects; D007279:Injections, Subcutaneous / Q000009:adverse effects*; D007328:Insulin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D012648:Self Care; D012869:Skin Absorption
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin